帯状疱疹ワクチン市場：製品、タイプ、流通チャネル別-2025-2030年の世界予測

帯状疱疹ワクチン市場は、2023年に17億3,000万米ドルと評価され、2024年には18億7,000万米ドルに達すると予測され、CAGR 8.11％で成長し、2030年には29億9,000万米ドルに達すると予測されています。

世界の帯状疱疹ワクチン市場は、特に50歳以上の帯状疱疹感染予防に焦点を当てて定義されています。帯状疱疹は水痘帯状疱疹ウイルス（水痘）の再活性化によって引き起こされ、帯状疱疹後神経痛などの重篤な合併症を軽減するためにワクチン接種が必要です。この市場を牽引しているのは、高齢者人口の増加、病気に対する意識の高まり、ワクチン技術の進歩です。主な用途としては、高齢者ヘルスケアや免疫不全患者管理での使用が挙げられます。エンドユーザーの採用は、病院、クリニック、専門ヘルスケアセンターなど多岐にわたる。成長要因としては、政府の積極的な取り組み、有利な償還政策、ヘルスケア支出の増加などが挙げられます。ワクチン接種率の低い新興市場、ワクチン株ターゲティング強化の機会、革新的なデリバリー方法のためのパートナーシップにビジネスチャンスがあります。現在推奨されているのは、摂取を促進するための教育プログラムを拡大し、高リスク層に的を絞ったマーケティング戦略を採用することです。しかし、製造コストの高さ、規制上のハードルの高さ、ワクチンの安全性に対する懐疑的な見方が、急速な市場浸透の妨げとなっています。さらに、ワクチン流通におけるロジスティクスの問題、ワクチンへのためらいの影響、ヘルスケア製品に定評のある大手製薬会社との競合といった課題もあります。技術革新のための注目すべき分野としては、長持ちするワクチン製剤の調査、免疫反応を改善する新しいアジュバント・システム、より迅速な製造時間と拡張性を提供できるmRNAベースのワクチン技術などがあります。戦略的な動きとしては、共同研究開発や、副作用を最小限に抑えながら包括的な予防効果を発揮する遺伝子組み換えワクチンへの投資が挙げられます。同市場は、グラクソ・スミスクラインやメルク・アンド・カンパニーといった大手企業の存在が際立つ競合情勢にあるが、ワクチン開発に人工知能などの技術的進歩を活用し、成長分野でニッチを切り開くことができる新規参入者の可能性を秘めたダイナミックな状況でもあります。

市場力学：急速に進化する帯状疱疹ワクチン市場の主要市場インサイトを公開

帯状疱疹ワクチン市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 慢性疾患の有病率の増加
  • 世界の老人人口の増加
  • 帯状疱疹の健康リスクに対する意識の高まりと予防接種への関心の高まり
• 市場抑制要因
  • ワクチン開発に必要な資本の高さ
• 市場機会
  • 帯状疱疹ワクチンに関する継続的な研究開発イニシアティブ
  • 世界の公衆衛生支出の大幅な増加
• 市場の課題
  • 帯状疱疹ワクチンに関連する副作用

ポーターのファイブフォース：帯状疱疹ワクチン市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：帯状疱疹ワクチン市場における外部からの影響の把握

外部マクロ環境要因は、帯状疱疹ワクチン市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析帯状疱疹ワクチン市場における競合情勢の把握

帯状疱疹ワクチン市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス帯状疱疹ワクチン市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、帯状疱疹ワクチン市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨帯状疱疹ワクチン市場における成功への道筋を描く

帯状疱疹ワクチン市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性疾患の増加
    • 世界中で高齢者人口が増加
    • 帯状疱疹の健康リスクに関する意識の高まりと予防接種への注目の高まり
  • 抑制要因
    • ワクチン開発には多額の資本が必要
  • 機会
    • 帯状疱疹ワクチンに関する継続的な研究開発の取り組み
    • 世界中で公衆衛生支出が大幅に増加
  • 課題
    • 帯状疱疹ワクチンに伴う副作用
• 市場セグメンテーション分析
  • 製品：安全性プロファイルの向上に向けたShingrixの重要性の高まり
  • タイプ：組み換え帯状疱疹ワクチンの利点を理解する
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 帯状疱疹ワクチン市場：製品別

• スカイゾスター
• ゾスタバックス
• シングリックス

第7章 帯状疱疹ワクチン市場：タイプ別

• 生弱毒化ワクチン
• 組み換えワクチン

第8章 帯状疱疹ワクチン市場：流通チャネル別

• ヘルスケアセンター
• 薬局

第9章 南北アメリカの帯状疱疹ワクチン市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の帯状疱疹ワクチン市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの帯状疱疹ワクチン市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • ダイナバックス、有望な帯状疱疹ワクチンZ-1018の臨床試験を開始
  • シノバック・バイオテック社、公衆衛生上の利益増大を目指してPROVARIXワクチンの承認を青少年と成人に拡大
  • GSK、Shingrixワクチンの承認を中国で若年成人に拡大、より広範な公衆衛生への影響を目指す
• 戦略分析と提言

企業一覧

• Astellas Pharma Inc.
• Barinthus Biotherapeutics plc
• Bavarian Nordic
• Biogenetech Co., Ltd.
• CanSino Biologics Inc.
• CSL Limited
• Curevo Inc.
• Daiichi Sankyo Company, Limited
• Dynavax Technologies Corporation
• Emergent Biosolutions Inc.
• GeneOne Life Science, Inc.
• Gilead Sciences, Inc.
• GlaxoSmithKline PLC
• Inovio Pharmaceuticals, Inc.
• JCR Pharmaceuticals Co., Ltd.
• Jiangsu Recbio Technology Co., Ltd.
• Merck KGaA
• Moderna, Inc.
• Pfizer Inc.
• Sanofi S.A.
• Sinovac Biotech Ltd.
• SK Chemicals
• Takeda Pharmaceutical Company Limited
• Valneva SE
• VBI Vaccines Inc.

LIST OF FIGURES

• FIGURE 1. SHINGLES VACCINE MARKET RESEARCH PROCESS
• FIGURE 2. SHINGLES VACCINE MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL SHINGLES VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL SHINGLES VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL SHINGLES VACCINE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL SHINGLES VACCINE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES SHINGLES VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES SHINGLES VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. SHINGLES VACCINE MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. SHINGLES VACCINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. SHINGLES VACCINE MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL SHINGLES VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL SHINGLES VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. SHINGLES VACCINE MARKET DYNAMICS
• TABLE 7. GLOBAL SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL SHINGLES VACCINE MARKET SIZE, BY SKYZOSTER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL SHINGLES VACCINE MARKET SIZE, BY ZOSTAVAX, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL SHINGLES VACCINE MARKET SIZE, BY SHINGRIX, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL SHINGLES VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL SHINGLES VACCINE MARKET SIZE, BY RECOMBINANT VACCINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL SHINGLES VACCINE MARKET SIZE, BY HEALTHCARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL SHINGLES VACCINE MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. AMERICAS SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 18. AMERICAS SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 21. ARGENTINA SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 22. ARGENTINA SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 24. BRAZIL SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 25. BRAZIL SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 27. CANADA SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 28. CANADA SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. CANADA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 30. MEXICO SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 31. MEXICO SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 33. UNITED STATES SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 34. UNITED STATES SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES SHINGLES VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 37. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 38. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 41. AUSTRALIA SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 42. AUSTRALIA SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 44. CHINA SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 45. CHINA SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 46. CHINA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 47. INDIA SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 48. INDIA SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. INDIA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 50. INDONESIA SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 51. INDONESIA SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 53. JAPAN SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 54. JAPAN SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 56. MALAYSIA SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 57. MALAYSIA SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 59. PHILIPPINES SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 60. PHILIPPINES SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 62. SINGAPORE SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 63. SINGAPORE SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 65. SOUTH KOREA SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 66. SOUTH KOREA SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 68. TAIWAN SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 69. TAIWAN SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 71. THAILAND SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 72. THAILAND SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 74. VIETNAM SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 75. VIETNAM SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 77. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 78. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA SHINGLES VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 81. DENMARK SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 82. DENMARK SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 84. EGYPT SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 85. EGYPT SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 87. FINLAND SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 88. FINLAND SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 90. FRANCE SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 91. FRANCE SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 93. GERMANY SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 94. GERMANY SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 96. ISRAEL SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 97. ISRAEL SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 99. ITALY SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 100. ITALY SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 101. ITALY SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 102. NETHERLANDS SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 103. NETHERLANDS SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 105. NIGERIA SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 106. NIGERIA SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 108. NORWAY SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 109. NORWAY SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 111. POLAND SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 112. POLAND SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. POLAND SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 114. QATAR SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 115. QATAR SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 116. QATAR SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 117. RUSSIA SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 118. RUSSIA SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 120. SAUDI ARABIA SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 121. SAUDI ARABIA SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 123. SOUTH AFRICA SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 124. SOUTH AFRICA SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 126. SPAIN SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 127. SPAIN SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 129. SWEDEN SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 130. SWEDEN SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 132. SWITZERLAND SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 133. SWITZERLAND SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 135. TURKEY SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 136. TURKEY SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 138. UNITED ARAB EMIRATES SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 139. UNITED ARAB EMIRATES SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 141. UNITED KINGDOM SHINGLES VACCINE MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 142. UNITED KINGDOM SHINGLES VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM SHINGLES VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 144. SHINGLES VACCINE MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 145. SHINGLES VACCINE MARKET, FPNV POSITIONING MATRIX, 2023

The Shingles Vaccine Market was valued at USD 1.73 billion in 2023, expected to reach USD 1.87 billion in 2024, and is projected to grow at a CAGR of 8.11%, to USD 2.99 billion by 2030.

The global shingles vaccine market is defined by its focus on the prevention of herpes zoster infections, particularly among individuals aged 50 and above. Shingles, caused by the reactivation of the varicella-zoster virus (chickenpox), necessitates vaccination to mitigate severe complications such as postherpetic neuralgia. The market is driven by an increasing aged population, rising awareness about the disease, and advancements in vaccine technology. Key applications include its use in elderly healthcare and immunocompromised patient management. End-user adoption spans across hospitals, clinics, and specialty healthcare centers. Growth factors include robust government initiatives, favorable reimbursement policies, and escalating healthcare expenditure. Opportunities arise from emerging markets with low vaccination rates, opportunities for enhanced vaccine strain targeting, and partnerships for innovative delivery methods. Current recommendations focus on expanding educational programs to boost uptake and employing targeted marketing strategies to reach high-risk demographics. However, limitations include high production costs, stringent regulatory hurdles, and public skepticism over vaccine safety that may hamper rapid market penetration. Additional challenges involve logistical issues in vaccine distribution, impact of vaccine hesitancy, and competition from existing pharmaceutical giants with entrenched healthcare products. Remarkable areas for innovation include research into long-lasting vaccine formulations, novel adjuvant systems to improve immune response, and mRNA-based vaccine technologies, which can offer faster production times and scalability. The strategic movement involves collaborative R&D and investment in genetically engineered vaccines that provide comprehensive coverage with minimal side effects. The market exhibits a competitive nature marked by the presence of major players like GlaxoSmithKline and Merck & Co., but it also presents a dynamic landscape with potential for new entrants who can leverage technological advancements, such as artificial intelligence for vaccine development, to carve out a niche in a growing sector.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Shingles Vaccine Market

The Shingles Vaccine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of chronic diseases
  • Rising number of geriatric population worldwide
  • Rising awareness about shingles health risks and growing focus on immunization
• Market Restraints
  • High capital requirements for vaccine development
• Market Opportunities
  • Ongoing Research & development initiatives on shingles vaccines
  • Significantly increasing public health expenditure worldwide
• Market Challenges
  • Adverse effects associated with shingles vaccines

Porter's Five Forces: A Strategic Tool for Navigating the Shingles Vaccine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Shingles Vaccine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Shingles Vaccine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Shingles Vaccine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Shingles Vaccine Market

A detailed market share analysis in the Shingles Vaccine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Shingles Vaccine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Shingles Vaccine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Shingles Vaccine Market

A strategic analysis of the Shingles Vaccine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Shingles Vaccine Market, highlighting leading vendors and their innovative profiles. These include Astellas Pharma Inc., Barinthus Biotherapeutics plc, Bavarian Nordic, Biogenetech Co., Ltd., CanSino Biologics Inc., CSL Limited, Curevo Inc., Daiichi Sankyo Company, Limited, Dynavax Technologies Corporation, Emergent Biosolutions Inc., GeneOne Life Science, Inc., Gilead Sciences, Inc., GlaxoSmithKline PLC, Inovio Pharmaceuticals, Inc., JCR Pharmaceuticals Co., Ltd., Jiangsu Recbio Technology Co., Ltd., Merck KGaA, Moderna, Inc., Pfizer Inc., Sanofi S.A., Sinovac Biotech Ltd., SK Chemicals, Takeda Pharmaceutical Company Limited, Valneva SE, and VBI Vaccines Inc..

Market Segmentation & Coverage

This research report categorizes the Shingles Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across SkyZoster, Zostavax, and Shingrix.
• Based on Type, market is studied across Live Attenuated Vaccine and Recombinant Vaccine.
• Based on Distribution Channel, market is studied across Healthcare Centers and Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of chronic diseases
    • 5.1.1.2. Rising number of geriatric population worldwide
    • 5.1.1.3. Rising awareness about shingles health risks and growing focus on immunization
  • 5.1.2. Restraints
    • 5.1.2.1. High capital requirements for vaccine development
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing Research & development initiatives on shingles vaccines
    • 5.1.3.2. Significantly increasing public health expenditure worldwide
  • 5.1.4. Challenges
    • 5.1.4.1. Adverse effects associated with shingles vaccines
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Rising significance of Shingrix for higher safety profile
  • 5.2.2. Type: Understanding the benefits of recombinant shingles vaccines
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Shingles Vaccine Market, by Product

• 6.1. Introduction
• 6.2. SkyZoster
• 6.3. Zostavax
• 6.4. Shingrix

7. Shingles Vaccine Market, by Type

• 7.1. Introduction
• 7.2. Live Attenuated Vaccine
• 7.3. Recombinant Vaccine

8. Shingles Vaccine Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Healthcare Centers
• 8.3. Pharmacies

9. Americas Shingles Vaccine Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Shingles Vaccine Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Shingles Vaccine Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Dynavax Begins Clinical Trial for Promising Shingles Vaccine, Z-1018
  • 12.3.2. Sinovac Biotech Ltd. Expands PROVARIX Vaccine Approval to Adolescents and Adults, Targeting Increased Public Health Benefits
  • 12.3.3. GSK Expands Shingrix Vaccine Approval to Younger Adults in China, Targets Broader Public Health Impact
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Astellas Pharma Inc.
• 2. Barinthus Biotherapeutics plc
• 3. Bavarian Nordic
• 4. Biogenetech Co., Ltd.
• 5. CanSino Biologics Inc.
• 6. CSL Limited
• 7. Curevo Inc.
• 8. Daiichi Sankyo Company, Limited
• 9. Dynavax Technologies Corporation
• 10. Emergent Biosolutions Inc.
• 11. GeneOne Life Science, Inc.
• 12. Gilead Sciences, Inc.
• 13. GlaxoSmithKline PLC
• 14. Inovio Pharmaceuticals, Inc.
• 15. JCR Pharmaceuticals Co., Ltd.
• 16. Jiangsu Recbio Technology Co., Ltd.
• 17. Merck KGaA
• 18. Moderna, Inc.
• 19. Pfizer Inc.
• 20. Sanofi S.A.
• 21. Sinovac Biotech Ltd.
• 22. SK Chemicals
• 23. Takeda Pharmaceutical Company Limited
• 24. Valneva SE
• 25. VBI Vaccines Inc.